Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $76.3 million.

  • Pliant Therapeutics' Total Liabilities fell 2358.6% to $76.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.3 million, marking a year-over-year decrease of 2358.6%. This contributed to the annual value of $92.9 million for FY2024, which is 14072.79% up from last year.
  • Per Pliant Therapeutics' latest filing, its Total Liabilities stood at $76.3 million for Q3 2025, which was down 2358.6% from $79.7 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' Total Liabilities registered a high of $99.8 million during Q3 2024, and its lowest value of $11.1 million during Q1 2021.
  • In the last 5 years, Pliant Therapeutics' Total Liabilities had a median value of $38.6 million in 2023 and averaged $50.6 million.
  • As far as peak fluctuations go, Pliant Therapeutics' Total Liabilities soared by 21382.92% in 2022, and later tumbled by 2358.6% in 2025.
  • Over the past 5 years, Pliant Therapeutics' Total Liabilities (Quarter) stood at $22.2 million in 2021, then surged by 68.22% to $37.3 million in 2022, then increased by 3.51% to $38.6 million in 2023, then skyrocketed by 140.73% to $92.9 million in 2024, then decreased by 17.85% to $76.3 million in 2025.
  • Its Total Liabilities stands at $76.3 million for Q3 2025, versus $79.7 million for Q2 2025 and $87.6 million for Q1 2025.